Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Filings indexed 3,164 across all filing types
Latest filing 2025-12-09 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings
2025-12-09 English
Lupin Receives Tentative Approval from U.S. FDA for Siponimod Tablets.
Regulatory Filings
2025-12-05 English
Press Release
Regulatory Filings
2025-12-05 English
Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States.
Regulatory Filings
2025-12-04 English
Press Release
Regulatory Filings
2025-12-04 English
Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg (Pegfilgrastim-unne).
Regulatory Filings
2025-12-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.